曙光？Moderna疫苗有效率94.5％
继辉瑞月初宣布冠状病毒疫苗90％有效以后，本月第二次传来候选COVID-19疫苗的好消息：Moderna周一表示，其疫苗有效率为94.5％，目前两家公司都有望在几周内寻求美国监管当局批准紧急使用许可。Moderna预计到2020年底将为美国提供约2000万剂疫苗。
For the second time this month, there's promising news about a COVID-19 vaccine candidate: Moderna said For the second time this month, there's promising news about a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the United States and around the world. The vaccine is among those Canada has preordered for its population.
Moderna said its vaccine appears to be 94.5 per cent effective, according to preliminary data from the company's still-ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the United States.
Kate O'Brien, director of the immunization department at the World Health Organization (WHO), said the preliminary results for both vaccines were "incredibly exciting."
"Both have reported over 90 per cent efficacy, which is really extraordinary and really meaningful," she told CBC News in a phone interview from Geneva.
"But we do have to remember that these are both based on short-term results after having been immunized.… Would that efficacy hold up over a period of weeks, months or even years?"
Moderna president Dr. Stephen Hoge welcomed the "really important milestone," but said having similar results from two different companies is what's most reassuring.
"It won't be Moderna alone that solves this problem. It's going to require many vaccines," to meet the global demand, he said.
its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the United States and around the world. The vaccine is among those Canada has preordered for its population.
Moderna said its vaccine appears to be 94.5 per cent effective, according to preliminary data from the company's still-ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the United States.
Kate O'Brien, director of the immunization department at the World Health Organization (WHO), said the preliminary results for both vaccines were "incredibly exciting."
"Both have reported over 90 per cent efficacy, which is really extraordinary and really meaningful," she told CBC News in a phone interview from Geneva.
"But we do have to remember that these are both based on short-term results after having been immunized.… Would that efficacy hold up over a period of weeks, months or even years?"
Moderna president Dr. Stephen Hoge welcomed the "really important milestone," but said having similar results from two different companies is what's most reassuring.
"It won't be Moderna alone that solves this problem. It's going to require many vaccines," to meet the global demand, he said.
For the second time this month, there's promising news about a COVID-19 vaccine candidate: Moderna said For the second time this month, there's promising news about a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the United States and around the world. The vaccine is among those Canada has preordered for its population.
Moderna said its vaccine appears to be 94.5 per cent effective, according to preliminary data from the company's still-ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the United States.
Kate O'Brien, director of the immunization department at the World Health Organization (WHO), said the preliminary results for both vaccines were "incredibly exciting."
"Both have reported over 90 per cent efficacy, which is really extraordinary and really meaningful," she told CBC News in a phone interview from Geneva.
"But we do have to remember that these are both based on short-term results after having been immunized.… Would that efficacy hold up over a period of weeks, months or even years?"
Moderna president Dr. Stephen Hoge welcomed the "really important milestone," but said having similar results from two different companies is what's most reassuring.
"It won't be Moderna alone that solves this problem. It's going to require many vaccines," to meet the global demand, he said.
its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the United States and around the world. The vaccine is among those Canada has preordered for its population.
Moderna said its vaccine appears to be 94.5 per cent effective, according to preliminary data from the company's still-ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the United States.
Kate O'Brien, director of the immunization department at the World Health Organization (WHO), said the preliminary results for both vaccines were "incredibly exciting."
"Both have reported over 90 per cent efficacy, which is really extraordinary and really meaningful," she told CBC News in a phone interview from Geneva.
"But we do have to remember that these are both based on short-term results after having been immunized.… Would that efficacy hold up over a period of weeks, months or even years?"
Moderna president Dr. Stephen Hoge welcomed the "really important milestone," but said having similar results from two different companies is what's most reassuring.
"It won't be Moderna alone that solves this problem. It's going to require many vaccines," to meet the global demand, he said.
